Today at #ASCO26, our team presented updated Phase 2 data on FID-007 + cetuximab. Thank you to the patients, investigators, and partners who made this possible. A Phase 3 study is planned.
Full release: https://t.co/beB355tQ0S
Interim Phase 2 data on FID-007 in combination with cetuximab show a 60% objective response rate and favorable safety in R/M #HNSCC.
Read the full abstract now on the ASCO 2026 site, and learn more at: https://t.co/qWSeabJAWM
#ASCO26
Headed to #ASCO26? Stop by booth #11094 to meet us.
We support clinical oncology teams with solid tumor NGS (incl. MSI/TMB), heme panels, ctDNA, HRR/HRD, germline, and IHC/FISH — across CLIA/CAP labs in the US, Australia, and China.
#PrecisionOncology#PrecisionMedicine
We Have Everything Under the Sea 🌊 Catch us at #APG2026's Exhibit Fair & Strolling Dinner — Thursday 5/28, 6:00–9:00 PM in San Diego. #FulgentGenetics
May is #EDSAwarenessMonth. Two panel updates from Fulgent: our EDS Panel now includes 39 genes across all 13 EDS types, and our Comprehensive Connective Tissue Disease Panel covers 119 genes, including EDS, Marfan, Loeys-Dietz, Stickler, and TAAD. #GeneticTesting
Our infertility NGS panels just got broader:
✓ Female Infertility Panel: +41 genes (now 143) — incl. all OZEMA genes
✓ Male Infertility Panel: +17 genes (now 163)
Pair with #BeaconCarrierScreening for a fuller picture. One partner, every step.
https://t.co/RtBPgeHPLY
Lab workers are the all-too-often unsung heroes of healthcare. So this #labweek, we'd like to express our gratitude to the Fulgent lab staff who work tirelessly behind the scenes on behalf of patients and the healthcare community. Thank you for all you do.
The latest findings on the efficacy of Fulgent's nano-encapsulated anti-tumor drug FID-007 will be presented at this year's American Society of Clinical Oncology (@ASCO) meeting.
https://t.co/IkwWHOFoyW
We’re at #AACR26! Visit Booth # 4354 to connect with our team about oncology services for clinical care and research, including Olink proteomics, IDVR NGS panels, and TSO500 v2 + HRD tumor profiling. Let’s explore collaboration! #NGS#Oncology#Biomarkers#Proteomics
Meet us at #AACR26 Booth 4354! See why Fulgent is trusted by top pharma for drug discovery, assay validation, and clinical translation.
Explore our multiomic solutions: CE-IVDR NGS panels, TSO500 v2 + HRD, and Olink® proteomics.
Schedule with us at: [email protected]
Fulgent Genetics is excited to attend the upcoming #ADPD2026 Conference in Copenhagen! If you’re attending AD/PD, we’d love to meet and explore how Fulgent can support your clinical practice, research programs, or global trial needs.
Tomorrow at #ACMG26, catch Beyond DNA: How RNA Changes the Game in Genomic Medicine with Jamie Zdrodowski, MS, CGC, and Katherine Roth, MD at the Exhibition Theater, 10:45 – 11:15 am.
Then stop by Booth #2010 for our complimentary wine bar, poster abstracts, and new product info.
#ACMG26 will be a big event! Our genetic counselors will present three poster abstracts.
Don’t miss the live talk on RNA’s impact on genomic medicine at the Exhibition Theater (Thurs, Mar 12, 10:45 AM ET).
Then stop by Booth #2010 for a complimentary wine bar!
We’re excited to connect at ACMG! Visit our three poster abstracts.
Jay Shaw presents a RISE case report showing how RNA-seq detects aberrant splicing, refines variant classification, and improves molecular diagnoses.
Poster #P043.
Mar 12, 10:30–11:30 AM ET.
We’re excited to connect at ACMG! Visit our three poster abstracts.
Jay Shaw presents a RISE case report showing how RNA-seq detects aberrant splicing, refines variant classification, and improves molecular diagnoses.
Poster #P043.
Mar 12, 10:30–11:30 AM ET.
Catch Jamie Zdrodowski’s poster #P780 at ACMG! Learn about the detection of a COL11A1 variant on prenatal cfDNA screening. Join us on Mar 13, 10:30am – 11:30am ET for insights and Q&A.
Follow for more #ACMG26 updates!
We’re excited to present three poster abstracts at ACMG.
Mitchell Dillon analyzed 240 probands using parallel RNAseq + DNA sequencing to improve variant prioritization, reduce VUS, and boost diagnostic yield.
Poster #P608
Mar 13, 10:30–11:30 AM
Follow us for more updates.
We’re excited to present three poster abstracts at ACMG.
Mitchell Dillon analyzed 240 probands using parallel RNAseq + DNA sequencing to improve variant prioritization, reduce VUS, and boost diagnostic yield.
Poster #P608, Mar 13, 10:30–11:30 AM
Follow us for more updates.